Trendlines Group
VC Fund
Misgav, Israel
Trendlines Group is a VC fund in Misgav focused on Health Care and Biotechnology. Trendlines Group invents, discovers, invests in, and incubates innovation-based medical and agrifood technologies. Trendlines invests principally through medical and agrifood incubators in Israel and in Singapore, its in-house innovation center, Trendlines Labs, and its Funds - the Trendlines Agrifood Fund and the Bayer Trendlines Ag InnovationFund.The company was founded in 1993 and is headquartered in Misgav, Israel.
- Total investments:
- 70
- Last investment:
- Lead investor:
- 21%
- Fund size:
- $40M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Trendlines Group invests in
Stages Trendlines Group invests in
Countries Trendlines Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $650k–$4.1M
- Series A
- $2.3M–$15M
Investment Focus
Industry
- Health Care 19 (27%)
- Biotechnology 18 (26%)
- Medical Device 13 (19%)
- Medical 12 (17%)
- AgTech 11 (16%)
Stage
- Seed 24 (34%)
- Funding Round 13 (19%)
- Series A 9 (13%)
- Venture - Series Unknown 7 (10%)
- Series B 5 (7%)
Country
- Israel 42 (60%)
- Singapore 3 (4%)
- United Kingdom 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Eric Loh
CEO, Trendlines Medical Singapore
|
CEO, Trendlines Medical Singapore | Total investments: 0 | Find email | |
Steve Rhodes
Chairman & CEO
|
Chairman & CEO | Total investments: 0 | Find email | |
Todd Dollinger
CEO
|
CEO | Total investments: 1 | Find email | |
Barak Singer
CEO, Trendlines Incubators Israel
|
CEO, Trendlines Incubators Israel | Total investments: 3 | Find email | |
Moshe Katzenelson
VP Business Development
|
VP Business Development | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
IBI-Ag
|
IBI-Ag is a biotechnology company developing a new class of bioinsecticides. IBI-Ag is focused on the discovery and development of new types of biological solutions that utilize environmentally friendly technology to control insects. IBI-Ag utilizes breakthrough technology to produce efficient, selective, and safe bio-insect control solutions.IBI-Ag technology is highly cost-effective due to its fermentation suitability enabling farmers to produce agricultural produce at a low cost. | $3.9M / Series A / Nov 11, 2025 | |
Phytolon
|
Phytolon revolutionizes the way food colors are produce, by Leveraging a novel and sustainable technology for production of healthy food colors in high quality at low costs. Phytolon's mission is to exploit scientific advancement promote human health and environmental sustainability | Aug 13, 2025 | |
|
IBI-Ag
|
IBI-Ag is a biotechnology company developing a new class of bioinsecticides. IBI-Ag is focused on the discovery and development of new types of biological solutions that utilize environmentally friendly technology to control insects. IBI-Ag utilizes breakthrough technology to produce efficient, selective, and safe bio-insect control solutions.IBI-Ag technology is highly cost-effective due to its fermentation suitability enabling farmers to produce agricultural produce at a low cost. | $6.1M / Series A / Feb 13, 2025 | |
Arcuro Medical
|
Arcuro develops a new repair system for meniscus tears of the knee. Arcuro’s proprietary SuperBall repair system consists of a knotless, all-suture anchor and innovative delivery system. The company was founded in 2013. | Series A / Jan 06, 2025 | |
|
Celleste Bio
|
Celleste is a business that specializes in employing cell culture techniques to produce high-value cocoa ingredients, removing the need for cocoa trees to be grown. | $4.5M / Seed / Dec 05, 2024 | |
|
AgriG8
|
AgriG8 is an enterprise designed to align, collaborate, de-risk and grow value chains and ecosystems within the agricultural industry. | Venture - Series Unknown / Jun 11, 2024 | |
Peptobiotics
|
Peptobiotics is a synbio startup that develops livestock disease prevention biotechnology for sustainable Agri productivity. The company makes agriculture more productive, humane, and sustainable by promoting growth and protecting against pathogens using a new type of antibiotic alternative that does not cause resistance. | $6.2M / Series A / Apr 09, 2024 | |
ViAqua Therapeutics
|
ViAqua Therapeutics Ltd develops drugs and therapeutics for aquaculture. The company was founded in 2014 and is based in Israel.ViAqua Therapeutics is developing the first orally administered treatment for aquaculture.The Company’s management bring a broad range of business development, technology development, management, and industrial biotechexperience. | $8.3M / Venture - Series Unknown / Sep 05, 2023 | |
Insectta
|
Insectta was founded in 2017 and produces materials from insects which can be applied across industries such as agrifood, pharmaceutical and electronics. | $1M / Venture - Series Unknown / Apr 28, 2023 | |
|
Celleste Bio
|
Celleste is a business that specializes in employing cell culture techniques to produce high-value cocoa ingredients, removing the need for cocoa trees to be grown. | Seed / Nov 07, 2022 | |
| See all 70 investments → | |||
Co-Investors
Israel Innovation Authority
8 deals together
Consensus Business Group
6 deals together
S2G Investments
4 deals together
EIT Food
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Trendlines Group invest in?
Trendlines Group invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed and Funding Round stage. Most of the 70 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Trendlines Group's check size?
Trendlines Group typically joins rounds of $650k–$4.1M at Seed and $2.3M–$15M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Trendlines Group participates in.
How do I contact Trendlines Group?
Public channels for Trendlines Group include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Trendlines Group?
The team at Trendlines Group includes Eric Loh (CEO, Trendlines Medical Singapore), Steve Rhodes (Chairman & CEO) and Todd Dollinger (CEO), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
